JP2025500338A - 細胞へのｒｎａの送達のためのアルファレトロウイルスをベースとする粒子 - Google Patents

細胞へのｒｎａの送達のためのアルファレトロウイルスをベースとする粒子 Download PDF

Info

Publication number
JP2025500338A
JP2025500338A JP2024537348A JP2024537348A JP2025500338A JP 2025500338 A JP2025500338 A JP 2025500338A JP 2024537348 A JP2024537348 A JP 2024537348A JP 2024537348 A JP2024537348 A JP 2024537348A JP 2025500338 A JP2025500338 A JP 2025500338A
Authority
JP
Japan
Prior art keywords
alpharetrovirus
rna
nucleotides
seq
gag
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024537348A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025500338A5 (https=
Inventor
シャムバッハ・アクセル
ガラ・メラニー
バロン・イヴォンヌ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medizinische Hochschule Hannover
Original Assignee
Medizinische Hochschule Hannover
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medizinische Hochschule Hannover filed Critical Medizinische Hochschule Hannover
Publication of JP2025500338A publication Critical patent/JP2025500338A/ja
Publication of JP2025500338A5 publication Critical patent/JP2025500338A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/11011—Alpharetrovirus, e.g. avian leucosis virus
    • C12N2740/11022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/11011—Alpharetrovirus, e.g. avian leucosis virus
    • C12N2740/11041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/11043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2024537348A 2021-12-21 2022-12-21 細胞へのｒｎａの送達のためのアルファレトロウイルスをベースとする粒子 Pending JP2025500338A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21216354.7A EP4202048A1 (en) 2021-12-21 2021-12-21 Alpharetrovirus-based particles for delivery of rna into cells
EP21216354.7 2021-12-21
PCT/EP2022/087224 WO2023118290A1 (en) 2021-12-21 2022-12-21 Alpharetrovirus-based particles for delivery of rna into cells

Publications (2)

Publication Number Publication Date
JP2025500338A true JP2025500338A (ja) 2025-01-09
JP2025500338A5 JP2025500338A5 (https=) 2025-12-22

Family

ID=80122564

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024537348A Pending JP2025500338A (ja) 2021-12-21 2022-12-21 細胞へのｒｎａの送達のためのアルファレトロウイルスをベースとする粒子

Country Status (5)

Country Link
US (1) US20250333759A1 (https=)
EP (2) EP4202048A1 (https=)
JP (1) JP2025500338A (https=)
CA (1) CA3239778A1 (https=)
WO (1) WO2023118290A1 (https=)

Also Published As

Publication number Publication date
EP4453225A1 (en) 2024-10-30
EP4202048A1 (en) 2023-06-28
US20250333759A1 (en) 2025-10-30
CA3239778A1 (en) 2023-06-29
WO2023118290A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
Wanisch et al. Integration-deficient lentiviral vectors: a slow coming of age
Mátrai et al. Recent advances in lentiviral vector development and applications
Chira et al. Progresses towards safe and efficient gene therapy vectors
Breckpot et al. Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics
KR102091957B1 (ko) 레트로바이러스 생산을 위한 안정한 세포주
CN109415415B (zh) 用于衣壳化基因组工程系统的颗粒
CA3120282A1 (en) Fusosome compositions for hematopoietic stem cell delivery
US20080241929A1 (en) Method and means for producing high titer, safe, recombinant lentivirus vectors
RS56844B1 (sr) Retrovirusni vektori sa modifikovanim polipurinskim nizom
CN107949640A (zh) 含有反向取向人泛素c启动子的逆转录病毒载体
Ghani et al. Generation of high-titer self-inactivated γ-retroviral vector producer cells
Negre et al. Lentiviral vectors derived from simian immunodeficiency virus
Cockrell et al. HIV-1 vectors: fulfillment of expectations, further advancements, and still a way to go
US9840720B2 (en) Materials and methods relating to packaging cell lines
US20250333759A1 (en) Alpharetrovirus-based particles for delivery of rna into cells
US20100221791A1 (en) Method for Incorporating Proteins Into Lentivirus Vectors
Schambach et al. Retroviral vectors for cell and gene therapy
van Heuvel Optimization of retroviral packaging cells for scale-up of vector production
US20250313829A1 (en) Compositions comprising cell lines and methods of generating viral particles using the same
EP4600357A1 (en) Delivery system for gene editing tools
Kloke et al. Functional HIV‐2‐and SIVsmmPBj‐derived lentiviral vectors generated by a novel polymerase chain reaction‐based approach
Tschorn Development of transposon and retrovirus-derived vectors for the rapid establishment of efficient producer cell lines
Durosa et al. g-RETROVIRUS-AND LENTIVIRUS-DERIVED VECTORS FOR GENE TRANSFER AND THERAPY
Heuvel Optimization of retroviral packaging cells for scale-up of vector production
WO2025137322A1 (en) Secreted particle information transfer (spit) system for genetic engineering

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251212